Pharmacokinetics, immunogenicity and safety of bivatuzumab mertansine, a novel CD44v6-targeting immunoconjugate, in patients with squamous cell carcinoma of the head and neck.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples